Tamari H, Ohtani Y, Higashi A, Miyoshino S, Matsuda I
Brain Dev. 1982;4(2):137-43. doi: 10.1016/s0387-7604(82)80007-7.
The treatment with xanthine oxidase inhibitor, allopurinol, was evaluated in 17 patients with Duchenne muscular dystrophy (aged 2 years 9 months to 13 years 9 months) using the double blind technique. The total observed period was 27 months. The results of 100-point scale of graded functional abilities revealed that an improvement, unchange and progression of dysfunction were found in 2, 2 and 6 patients, respectively, in allopurinol group and in 0, 2 and 5 patients, respectively in placebo group. The patients' age and stage of the disease seemed to be related to the effectiveness or allopurinol treatment.
采用双盲技术对17例杜氏肌营养不良症患者（年龄在2岁9个月至13岁9个月之间）进行了黄嘌呤氧化酶抑制剂别嘌醇治疗的评估。总观察期为27个月。功能能力分级100分制的结果显示，别嘌醇组分别有2例、2例和6例患者功能改善、无变化和功能障碍进展，安慰剂组分别有0例、2例和5例患者出现上述情况。患者的年龄和疾病阶段似乎与别嘌醇治疗的有效性有关。
